Browse Technologies

• 
• 
• 
• 

Vanderbilt researchers have created the first isoform-selective phospholipase D (PLD) inhibitors. These highly potent inhibitors can significantly reduce PLD activity, creating a new class of anti-metastatic agents.

Inhibitors of histone acetylation may constitute a novel class of potent therapy sensitizers applicable to a broad range of conventional cancer treatments.

Vanderbilt scientists have discovered that the receptor tyrosine phosphatase DEP-1 plays a significant role in angiogenesis and that modulation of the DEP-1 receptor with certain agents can affect endothelial cell growth. The research team has developed antibodies that bind to the ectodomain of a mammalian transmembrane protein known as DEP-1 (for density enhanced protein) or CD148. CD148 (also named DEP-1/PTPn) is a receptor-like protein tyrosine phosphatase that is abundantly expressed in vascular endothelial cells, hematopoietic-cell lineages, duct epithelia of thyroid, mammary and gastrointestinal tissues.

Dravet syndrome is a lifelong form of epilepsy beginning in early childhood. Children with Dravet syndrome suffer aggressive seizures, impaired cognition, and an increased risk of premature death. Dravet syndrome does not respond to conventional anti-epileptic drugs, and current treatment regimens fail to fully elevate seizures. No disease modifying treatments exist. Researchers at Vanderbilt University have discovered a novel application of a known natural product in treating Dravet syndrome. This natural product could be beneficial to children suffering from Dravet syndrome in both reducing seizures and treating the underlying disease cause.